Tricor: Advanced Triglyceride Control for Cardiovascular Health
Tricor (fenofibrate) is a leading lipid-regulating medication specifically designed to address hypertriglyceridemia and mixed dyslipidemia. As a fibric acid derivative, it works by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances the breakdown and elimination of triglyceride-rich particles from the bloodstream. Clinically proven to significantly reduce elevated triglyceride levels while increasing HDL cholesterol, Tricor represents a cornerstone in lipid management therapy for appropriate patient populations. Its targeted mechanism of action makes it particularly valuable for patients who haven’t achieved optimal lipid control through lifestyle modifications alone or who require adjunct therapy to statins in specific clinical scenarios.
Features
- Contains fenofibrate as the active pharmaceutical ingredient
- Available in multiple strengths: 48 mg and 145 mg tablets
- Micronized formulation for enhanced bioavailability
- Once-daily dosing regimen for patient convenience
- FDA-approved for treating severe hypertriglyceridemia
- Compatible with many other cardiovascular medications
- Manufactured under strict quality control standards
- Multiple generic equivalents available
- Temperature-stable formulation
- Child-resistant packaging options
Benefits
- Significantly reduces elevated triglyceride levels by up to 50% in responsive patients
- Increases HDL (“good”) cholesterol levels, improving overall lipid profile
- May reduce cardiovascular risk in selected patient populations when combined with comprehensive risk factor management
- Convenient once-daily dosing supports medication adherence and treatment consistency
- Well-tolerated profile with extensive clinical experience spanning decades
- Can be used as monotherapy or in combination with statins in appropriate patients under medical supervision
Common use
Tricor is primarily prescribed for adult patients with severe hypertriglyceridemia (triglyceride levels ≥500 mg/dL) to reduce the risk of pancreatitis. It is also used as adjunctive therapy to diet in patients with mixed dyslipidemia (elevated LDL cholesterol, elevated triglycerides, and low HDL cholesterol) who haven’t achieved target lipid levels through lifestyle modifications alone. Physicians may consider Tricor for patients who cannot tolerate statins or who require additional triglyceride-lowering beyond what statins provide. The medication is typically incorporated into a comprehensive cardiovascular risk reduction strategy that includes dietary management, exercise, and treatment of other modifiable risk factors.
Dosage and direction
The recommended dosage of Tricor is individualized based on patient characteristics and treatment response. The usual starting dose for most patients is 145 mg taken once daily with meals to enhance absorption. For patients with renal impairment or elderly patients, a reduced initial dose of 48 mg daily may be appropriate. Dosage adjustments should be made based on lipid response at 4-8 week intervals, not exceeding the maximum recommended dose of 145 mg daily. Tablets should be swallowed whole with a full glass of water and not crushed or chewed. Consistent timing of administration is recommended to maintain stable drug levels. Treatment response should be monitored through periodic lipid panels, with dosage adjustments made under medical supervision.
Precautions
Patients taking Tricor should undergo regular monitoring of liver function tests before initiation and periodically during therapy, as fenofibrate may cause increases in liver transaminases. Renal function should be assessed before starting treatment and monitored regularly, particularly in elderly patients or those with pre-existing renal impairment. Tricor may increase serum creatinine levels, which should be monitored throughout treatment. Patients should be advised to report any unexplained muscle pain, tenderness, or weakness immediately, as these may signal rare but serious adverse effects. Regular ophthalmologic examinations are recommended, as fenofibrate may cause cataract formation. Blood counts should be monitored periodically due to potential hematologic effects.
Contraindications
Tricor is contraindicated in patients with hypersensitivity to fenofibrate or any component of the formulation. It should not be used in patients with hepatic impairment, including primary biliary cirrhosis and unexplained persistent liver function abnormalities. Severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73m²) represents another contraindication. The medication is contraindicated in patients with gallbladder disease, as fenofibrate may increase cholesterol secretion into bile and potentially promote gallstone formation. Tricor is not recommended during breastfeeding and should be avoided in combination with repaglinide due to increased risk of severe hypoglycemia.
Possible side effect
The most common side effects of Tricor include headache, abdominal pain, nausea, and respiratory disorders. Some patients may experience increased liver enzymes, which typically normalize with dosage reduction or discontinuation. Musculoskeletal effects such as back pain, arthralgia, and myalgia have been reported. Less frequently, patients may experience rash, pruritus, or photosensitivity reactions. Serious but rare side effects include pancreatitis, hepatitis, rhabdomyolysis, renal impairment, and venous thromboembolism. Hematologic changes such as decreased hemoglobin, hematocrit, and white blood cell count may occur. Some patients report increased creatinine levels, which usually stabilize during continued therapy.
Drug interaction
Tricor may potentiate the effects of oral anticoagulants like warfarin, requiring more frequent INR monitoring and possible dosage adjustment. Concomitant use with statins increases the risk of myopathy and rhabdomyolysis, particularly with higher statin doses. Bile acid sequestrants may reduce Tricor absorption and should be administered at least 2 hours apart. Cyclosporine may increase fenofibrate exposure and should be used with caution. Tricor may enhance the hypoglycemic effects of sulfonylureas and insulin, requiring blood glucose monitoring. The medication may interact with other highly protein-bound drugs, potentially altering their pharmacokinetics. Physicians should review all medications, including over-the-counter products and supplements, before initiating Tricor therapy.
Missed dose
If a dose of Tricor is missed, patients should take it as soon as they remember unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed one. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy. Consistency in medication timing is important for maintaining stable lipid levels, so patients should establish routines to support regular dosing. Use of pill organizers or medication reminders may help prevent missed doses.
Overdose
In case of suspected Tricor overdose, immediate medical attention should be sought. Symptoms may include abdominal discomfort, nausea, vomiting, and renal dysfunction. There is no specific antidote for fenofibrate overdose. Treatment should be supportive and symptomatic, including gastric lavage if ingestion was recent and activated charcoal administration. Hemodialysis is not expected to be effective due to Tricor’s high protein binding. Liver and renal function should be monitored closely, and appropriate supportive care provided based on clinical manifestations. Patients should be advised to store medication properly to prevent accidental ingestion by children or pets.
Storage
Tricor tablets should be stored at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other humid locations. Keep out of reach of children and pets. Do not use Tricor beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs or following specific disposal instructions.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Tricor is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and the benefits and risks should be carefully considered for each patient. Patients should not make changes to their medication regimen without consulting their physician. The complete prescribing information should be reviewed before initiating therapy. This summary may not include all possible information about Tricor, and healthcare providers should reference the full prescribing information for comprehensive guidance.
Reviews
Clinical studies demonstrate that Tricor effectively reduces triglyceride levels by 40-50% in responsive patients while increasing HDL cholesterol by 15-20%. Many patients report improved lipid profiles within the first month of treatment. Physicians note that Tricor is particularly valuable for patients with severely elevated triglycerides who are at risk for pancreatitis. Some patients report gastrointestinal discomfort during the initial treatment period, which often resolves with continued use. Long-term users appreciate the once-daily dosing convenience. Healthcare providers emphasize the importance of regular monitoring and lifestyle modifications alongside medication therapy for optimal outcomes. Patient satisfaction surveys indicate generally positive experiences when expectations are properly managed and monitoring protocols are followed.